LYEL — Lyell Immunopharma Cashflow Statement
0.000.00%
Last trade - 00:00
- $553.21m
- $6.99m
- $0.13m
- 43
- 17
- 63
- 35
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -129 | -204 | -250 | -183 | -235 |
Depreciation | |||||
Non-Cash Items | 56.8 | 39.6 | 106 | 77.6 | 47.3 |
Unusual Items | |||||
Equity in Net Earnings/Losses | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 111 | -0.336 | 4.01 | -82 | 3.42 |
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | 39.5 | -161 | -126 | -170 | -164 |
Capital Expenditures | -16 | -51.5 | -65.5 | -24.3 | -2.69 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -406 | -222 | -56.1 | 12.7 | 187 |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -422 | -274 | -122 | -11.5 | 184 |
Financing Cash Flow Items | — | — | — | -0.461 | -0.457 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Cash from Financing Activities | 351 | 477 | 401 | 10.6 | 1.74 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -31.8 | 42.4 | 153 | -170 | 22.1 |